Investigating how certain genetic factors affect breast cancer that doesn't respond to hormone therapy
Official title: Epigenetic dependencies and vulnerabilities in endocrine-resistant breast cancer
Funded at University of Miami School of Medicine · NIH-11049574 · Data updated 2026-11-12
This study is looking into why some breast cancers don't respond to hormone treatments and hopes to find new ways to help patients by understanding the genetic factors involved, so they can get better, more personalized care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $447,340 |
| NIH project number | 1R01CA288742-01A1 |
| Project ID | NIH-11049574 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with estrogen receptor-positive breast cancer who have developed resistance to hormone therapies.
✕Less likely to help
Patients with breast cancer that is not estrogen receptor-positive or those who have not undergone hormone therapy may not benefit from this research.
What this research studies
This research focuses on understanding the genetic and epigenetic factors that contribute to breast cancer's resistance to hormone therapies. Specifically, it examines the CoREST-SWI/SNF axis, which plays a role in how breast cancer cells adapt and survive despite treatment. By identifying these vulnerabilities, the research aims to develop new therapeutic strategies that could improve outcomes for patients with endocrine-resistant breast cancer. Patients may benefit from insights that lead to more effective treatments tailored to their specific cancer characteristics.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival rates for patients with endocrine-resistant breast cancer.
How similar studies have gone: Previous research has shown promise in targeting epigenetic mechanisms in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Morey, Lluis — University of Miami School of Medicine
- Study coordinator: Morey, Lluis
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.